Literature DB >> 24050066

The quality of antimalarial medicines in western Cambodia: a case study along the Thai-Cambodian border.

Souly Phanouvong1, Christopher Raymond, Laura Krech, Yanga Dijiba, Boravann Mam, Patrick Lukulay, Duong Socheat, Tey Sovannarith, Chroeng Sokhan.   

Abstract

The prevalence, availability, and use of antimalarial medicines (AMLs) were studied in six Cambodian provinces along the Thai-Cambodian border. The study was divided into two parts: the first looked at the quality of AMLs available in Pursat, Pailin, Battambang, Bantey Meanchey, Oddar Meanchey, and Preah Vihear and the second obtained information about the availability and use of AMLs. A randomized sampling methodology was used to select locations and collect samples, which were screened using Global Pharma Health Fund (GPHF) Minilabs. A subset of samples was sent to quality control laboratories for confirmatory testing. For the second part of the study, face-to-face interviews were conducted using standardized surveys with members of randomly selected households and staff of health facilities in the villages with highest malaria incidence to find out where they acquired their AMLs and which were most frequently used. The results showed an overall failure rate of 12.3% (n = 46 of 374 total AML samples). The causes of medication sample failure were low active pharmaceutical ingredient (API) content, failed dissolution properties, and unacceptably high levels of impurities. A total of 86.2% of survey respondents (n = 1,648 of 1,912) reported a member of their household having malaria in the previous year. The most commonly used medicines were paracetamol (67.1% of respondents), Malarine (A+M co-blistered, 28.6%), artesunate + mefloquine co-blistered (public sector product, 17.3%), quinine (16.7%), and artesunate monotherapy (11.9%). Health staff typically prescribed co-blistered artesunate plus mefloquine in the public sector (67.8%), the artesunate plus mefloquine "social marketing" product from Population Services International (PSI), Malarine (50.3%) in the private sector, artemether (49.7%), chloroquine (39%) and paracetamol (72.9%) to reduce fever.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24050066

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  13 in total

1.  The Medicines Quality Database: a free public resource.

Authors:  Laura A Krech; Latifa El-Hadri; Lawrence Evans; Tom Fouche; Mustapha Hajjou; Patrick Lukulay; Souly Phanouvong; Victor Pribluda; Lukas Roth
Journal:  Bull World Health Organ       Date:  2014-01-01       Impact factor: 9.408

2.  Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field study.

Authors:  Benjamin J Visser; Janneke Meerveld-Gerrits; Daniëlle Kroon; Judith Mougoula; Rieke Vingerling; Emmanuel Bache; Jimmy Boersma; Michèle van Vugt; Selidji T Agnandji; Harparkash Kaur; Martin P Grobusch
Journal:  Malar J       Date:  2015-07-15       Impact factor: 2.979

3.  Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia.

Authors:  Shunmay Yeung; Harriet L S Lawford; Patricia Tabernero; Chea Nguon; Albert van Wyk; Naiela Malik; Mikhael DeSousa; Ouk Rada; Mam Boravann; Prabha Dwivedi; Dana M Hostetler; Isabel Swamidoss; Michael D Green; Facundo M Fernandez; Harparkash Kaur
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

4.  Monitoring the quality of medicines: results from Africa, Asia, and South America.

Authors:  Mustapha Hajjou; Laura Krech; Christi Lane-Barlow; Lukas Roth; Victor S Pribluda; Souly Phanouvong; Latifa El-Hadri; Lawrence Evans; Christopher Raymond; Elaine Yuan; Lang Siv; Tuan-Anh Vuong; Kwasi Poku Boateng; Regina Okafor; Kennedy M Chibwe; Patrick H Lukulay
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

Review 5.  Interventions to combat or prevent drug counterfeiting: a systematic review.

Authors:  Fadi El-Jardali; Elie A Akl; Racha Fadlallah; Sandy Oliver; Nadine Saleh; Lamya El-Bawab; Rana Rizk; Aida Farha; Rasha Hamra
Journal:  BMJ Open       Date:  2015-03-18       Impact factor: 2.692

6.  Establishing research priorities for malaria elimination in the context of the emergency response to artemisinin resistance framework-the Cambodian approach.

Authors:  Sara E Canavati; Harriet L S Lawford; Bayo S Fatunmbi; Dysoley Lek; Narann Top-Samphor; Rithea Leang; Arjen M Dondorp; Rekol Huy; Walter M Kazadi
Journal:  Malar J       Date:  2016-02-25       Impact factor: 2.979

Review 7.  Anti-malarial medicine quality field studies and surveys: a systematic review of screening technologies used and reporting of findings.

Authors:  Mirza Lalani; Freddy Eric Kitutu; Siân E Clarke; Harparkash Kaur
Journal:  Malar J       Date:  2017-05-15       Impact factor: 2.979

8.  Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain.

Authors:  Manuel W Hetzel; Madhu Page-Sharp; Nancy Bala; Justin Pulford; Inoni Betuela; Timothy M E Davis; Evelyn K Lavu
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

9.  Degradation of Artemisinin-Based Combination Therapies Under Tropical Conditions.

Authors:  Zoe Hall; Elizabeth Louise Allan; Donelly Andrew van Schalkwyk; Albert van Wyk; Harparkash Kaur
Journal:  Am J Trop Med Hyg       Date:  2016-03-07       Impact factor: 2.345

10.  Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment.

Authors:  Sara E Canavati; Saranath Lawpoolsri; Cesia E Quintero; Chea Nguon; Po Ly; Sasithon Pukrittayakamee; David Sintasath; Pratap Singhasivanon; Koen Peeters Grietens; Maxine Anne Whittaker
Journal:  Malar J       Date:  2016-05-20       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.